Skip to content

A single-center, randomized controlled study of low-intensity pulsed ultrasound (LIPUS) in the treatment of patients with erectile dysfunction (ED) and chronic prostatitis (CP)

A single-center, randomized controlled study of low-intensity pulsed ultrasound (LIPUS) in the treatment of patients with erectile dysfunction (ED) and chronic prostatitis (CP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063038
Enrollment
Unknown
Registered
2022-08-29
Start date
2022-08-30
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction, chronic prostatitis

Interventions

Group 1 :LIPUS
Group 2:LIPUS + tadalafil + doxazosin
Group 3:tadalafil + doxazosin

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18 = 10 points and symptoms such as frequent urination and urination discomfort last for at least 6 months; 5. Those who have not used other methods including PDE5i to treat ED within 4 weeks before grouping; 6. Overall good health, having a stable heterosexual partner for more than 3 months; 7. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Organic ED; 2. Uncontrollable systemic hemorrhagic disease, medical history of bleeding tendency; 3. Severe arrhythmia in patients with poor blood pressure control (systolic blood pressure >= 160 mmHg and diastolic blood pressure >= 100 mmHg after treatment); 4. Patients with poor blood sugar control, that is, HbA1c >= 13%; 5. Unstable angina; 6. Diseases that hinder the safe participation of the experimental design and affect the completion of the study, such as myocardial infarction or stroke, congestive heart failure, severe chronic obstructive pulmonary disease, cancer, serious systemic disease and severe mental illness in the past 3 months; 7. Those who are allergic to the drugs in the test (doxazosin, tadalafil, etc.) or have contraindications (such as currently using anticoagulants and nitrates, etc.); 8. Recent (within 3 months) history of myocardial infarction; 9. Have a history of gastrointestinal obstruction, esophageal obstruction or any degree of narrowing of the lumen of the gastrointestinal tract; 10. Participating in other clinical research; 11. Other researchers think that they are not suitable for participating in this trial.

Design outcomes

Primary

MeasureTime frame
International Index of Erectile Function;Chronic Prostatitis Symptom Scale;

Countries

China

Contacts

Public ContactXiongbing Zu

Xiangya Hospital, Central South University

zuxbxyyy@126.com+86 13723887715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026